Loading Quotes...

News and Announcements

Closer look at TAILORx confirms lack of chemo benefit regardless of race or ethnicity; new study also finds blacks had worse outcomes than whites Read Press Release

Study E1912 proves that for CLL patients, the novel treatment of ibrutinib and rituximab is superior to standard care (chemotherapy)  Read Press Release

Forbes Magazine article on the results of NCI-MATCH (EAY131) substudy Y – capivasertib for patients with mutations of the AKT1 gene. Read Article

Genome Web article on substudy Y results. Read Article (requires free registration)

NCI-MATCH (EAY131) Update: More Labs, New Arms, and Initial Findings. Read NCI’s Cancer Currents Blog


President, American Society of Hematology

Martin S. Tallman, MD
Hematologic Oncologist and Chief, Leukemia Service

Memorial Sloan Kettering Cancer Center

Congratulations to Dr. Tallman, who chaired the ECOG-ACRIN Leukemia Committee for 16 years. Dr. Tallman will serve a one-year term as vice president of ASH, starting in December, followed by successive terms as president-elect and president.

We acknowledge Dr. Tallman for his tremendous leadership of the Leukemia Committee during his tenure from 1997-2013. Practice-changing studies in AML and other acute and chronic leukemias occurred during this time, and he greatly enhanced the scientific structure that supports the committee’s activities to this day.

Meet the 2018 Young Investigator Symposium presenters. Read More

The E2112 study recently reached its enrollment goal! Learn more about the trial for men and women with advanced breast cancer. Read More

Results of TAILORx released. Read Press Release

NCI-MATCH (EAY131) trial enrolling an average of 7-8 new patients weekly. Positive findings from substudy Y presented. Read Press Release

Results of NCI-MATCH (EAY131) substudies I, Q, and W released. Read Press Release

Webinar on patient-reported outcomes research by David Cella, PhD. View Here



Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

Robert L. Comis, MD
Group Co-Chair

Mitchell D. Schnall, MD, PhD
Group Co-Chair







img img